伊布替尼
套细胞淋巴瘤
布鲁顿酪氨酸激酶
医学
临床试验
肿瘤科
内科学
酪氨酸激酶
淋巴瘤
慢性淋巴细胞白血病
白血病
受体
作者
David A. Bond,Kami J. Maddocks
标识
DOI:10.1016/j.hoc.2020.06.007
摘要
The Bruton tyrosine kinase inhibitors (BTKi), acalabrutinib , ibrutinib , and zanubrutinib , are all approved in the United States for the treatment of relapsed mantle cell lymphoma (MCL). BTKi as a class have become the preferred therapy for most of the patients with relapsed MCL, and ongoing clinical trials are evaluating whether combining BTKi with other targeted agents may deepen response and further improve outcomes. Emerging evidence supports the efficacy of BTKi-containing combinations as frontline treatment, and clinical studies to define the role of this class of drugs for newly diagnosed patients with MCL are in progress.
科研通智能强力驱动
Strongly Powered by AbleSci AI